Page 196 - 2018_11-Haematologica-web

1936
haematologica | 2018; 103(11)
J.D. Lai et al.
Haemophilia. 2010;16 Suppl 5194-5199.
40. Böhm E, Seyfried BK, Dockal M, et al. Differences in N-glycosylation of recombi- nant human coagulation factor VII derived from BHK, CHO, and HEK293 cells. BMC Biotechnol. 2015;15:87.
41. Clerc F, Reiding KR, Jansen BC, Kammeijer GSM, Bondt A, Wuhrer M. Human plasma protein N-glycosylation. Glycoconj J. 2016;33(3):309-343.
42. Sodetz JM, Pizzo SV, McKee PA. Relationship of sialic acid to function and in vivo survival of human factor VIII/von Willebrand factor protein. J Biol Chem. 1977;252(15):5538-5546.
43. Pittman DD, Tomkinson KN, Kaufman RJ. Post-translational requirements for func- tional factor V and factor VIII secretion in mammalian cells. J Biol Chem. 1994;269(25):17329-17337.
44. Skupsky J, Zhang AH, Su Y, Scott DW. A role for thrombin in the initiation of the immune response to therapeutic factor VIII.
Blood. 2009;114(21):4741-4748.
45. Meeks SL, Cox CL, Healey JF, et al. A major determinant of the immunogenicity of fac- tor VIII in a murine model is independent of its procoagulant function. Blood. 2012;
120(12):2512-2520.
46. Ali SR, Fong JJ, Carlin AF, et al. Siglec-5 and
Siglec-14 are polymorphic paired receptors that modulate neutrophil and amnion sig- naling responses to group B Streptococcus. J Exp Med. 2014;211(6):1231-1242.
47. Purohit VS, Middaugh CR, Balasubramanian S V. Influence of aggrega- tion on immunogenicity of recombinant human Factor VIII in hemophilia A mice. J Pharm Sci. 2006;95(2):358-371.
48. Dasgupta S, Repesse Y, Bayry J, et al. VWF protects FVIII from endocytosis by dendrit- ic cells and subsequent presentation to immune effectors. Blood. 2007; 109(2):610- 612.
49. Hartholt RB, Wroblewska A, Herczenik E, et al. Enhanced uptake of blood coagulation
factor VIII containing immune complexes by antigen presenting cells. J Thromb Haemost. 2017;15(2):329-340.
50. McMullen ME, Hart ML, Walsh MC, Buras J, Takahashi K, Stahl GL. Mannose-binding lectin binds IgM to activate the lectin com- plement pathway in vitro and in vivo. Immunobiology. 2006;211(10):759-766.
51. Gilles JG, Saint-Remy JMR. Healthy sub- jects produce both anti-Factor VIII and spe- cific anti-idiotypic antibodies. J Clin Invest. 1994;94(4):1496-1505.
52. Hofbauer CJ, Whelan SFJ, Hirschler M, et al. Affinity of FVIII-specific antibodies reveals major differences between neutral- izing and nonneutralizing antibodies in humans. Blood. 2014;125(7):1180-1188.
53. Hofbauer CJ, Kepa S, Schemper M, et al. FVIII-binding IgG modulates FVIII half-life in patients with severe and moderate hemophilia A without inhibitors. Blood. 2016;128(2):293-296.